AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio.
Globus has introduced several new system extensions so far in 2024 and received 510(k) clearance from the U.S. Food and Drug Administration for its first suture-based product, TENSOR™ Suture Button System. Newly launched, next-generation systems include ANTHEM™ II Distal Radius Volar Plates, AUTOBAHN™ Trochanteric Nail PRO Instruments, and CAPTIVATE™ SOLA Headless Screws.
"The addition of these products to our growing orthopedic trauma portfolio signifies our continued responsiveness and dedication to surgeons and patients,” said John Mulcahy, Chief Commercial Officer and President of Orthopedics.
Surgeons across the U.S. have been implementing these new implants and instrument sets into their practices with positive feedback. Dr. Asif Ilyas, at Thomas Jefferson University Hospital, was one of the first users of the new ANTHEM™ II Volar plates. "The contour of the ANTHEM™ II Volar Plates and comprehensive fixation options allow me to further customize my surgical plans and achieve an anatomic fit,” said Dr. Ilyas. "I am excited for the continued use of the ANTHEM™ Distal Radius system in my practice.”
Globus Medical's orthopedic trauma business is rapidly growing. With these new technologies building out the product portfolio and the continued integration of the PRECICE™ magnetically actuated limb-lengthening nail technologies, there is more capacity to service a wide variety of patient needs with innovative solutions.
About TENSOR™ Suture Button System
The TENSOR™ Suture Button System is engineered to redefine suture management in the operating room. The system features a self-locking suture and an inserter with integrated tensioning handles, which provides a streamlined approach for tensioning through a single incision. TENSOR™ is compatible with ANTHEM™ Ankle and One-Third Tubular Plates, offering surgeons a complete ankle solution. The system also features a two-hole washer kit that can aid in the repair of isolated syndesmotic injuries.
About ANTHEM™ Distal Radius Fracture System
The ANTHEM™ Distal Radius Fracture System is a comprehensive fixation system designed to treat a wide variety of wrist fractures with anatomically contoured plates for intraoperative versatility. Market-leading polyaxial locking technology allows for ±20° of angulation (40° cone) in polyaxial volar, fragment specific, and diaphyseal metaphyseal plates. MonoAx™ locking technology enables a thin volar plate design to facilitate distal plate placement in the treatment of complex, intra-articular fractures. Innovative instruments allow for secure retraction and streamlined plate positioning, drilling, and screw insertion.
About AUTOBAHN™ Trochanteric Nail System
The AUTOBAHN™ Trochanteric Nailing System is designed to treat a variety of pertrochanteric femur fractures. The PRO Instrument Set and Distal Targeting System allow for an efficient and streamlined surgical workflow.
About CAPTIVATE SOLA Screw System
The CAPTIVATE™ SOLA Headless Compression Screw System offers a flexible and efficient solution to address fracture repair, bone reconstruction, osteotomy, and arthrodesis procedures through ample implant options and shared instruments for paired screw sizes. Screw diameters include 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.5, 6.5, and 7.5mm in lengths ranging from 10-140mm. All screws are available in stainless steel and titanium alloy, with options for short and long partial threads. Small and large modular graphic cases house all nine screw diameters and corresponding instrument modules.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe,” "may,” "might,” "could,” "will,” "aim,” "estimate,” "continue,” "anticipate,” "intend,” "expect,” "plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled "Risk Factors” and "Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Investor contact:
Brian Kearns
610-930-1800
Media contact:
Moran Chavez
